Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 21;25(20):4866.
doi: 10.3390/molecules25204866.

Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer's Disease

Eniko Manek  1 , Ferenc Darvas  2 , Georg A Petroianu  1
Affiliations
Review

Use of Biodegradable, Chitosan-Based Nanoparticles in the Treatment of Alzheimer's Disease

Eniko Manek et al. Molecules. .

Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that affects more than 24 million people worldwide and represents an immense medical, social and economic burden. While a vast array of active pharmaceutical ingredients (API) is available for the prevention and possibly treatment of AD, applicability is limited by the selective nature of the blood-brain barrier (BBB) as well as by their severe peripheral side effects. A promising solution to these problems is the incorporation of anti-Alzheimer drugs in polymeric nanoparticles (NPs). However, while several polymeric NPs are nontoxic and biocompatible, many of them are not biodegradable and thus not appropriate for CNS-targeting. Among polymeric nanocarriers, chitosan-based NPs emerge as biodegradable yet stable vehicles for the delivery of CNS medications. Furthermore, due to their mucoadhesive character and intrinsic bioactivity, chitosan NPs can not only promote brain penetration of drugs via the olfactory route, but also act as anti-Alzheimer therapeutics themselves. Here we review how chitosan-based NPs could be used to address current challenges in the treatment of AD; with a specific focus on the enhancement of blood-brain barrier penetration of anti-Alzheimer drugs and on the reduction of their peripheral side effects.

Keywords: Alzheimer’s disease; CNS delivery; amyloid-β; biodegradable; blood-brain barrier; chitosan; polymer nanoparticle.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structure of chitosan.
Scheme 1
Scheme 1
The enzymatic degradation of chitosan.
Figure 2
Figure 2
Chemical structure of rivastigmine.
Figure 3
Figure 3
Chemical structure of galantamine.
Figure 4
Figure 4
Chemical structure of tacrine.
Figure 5
Figure 5
Chemical structure of curcumin.
Figure 6
Figure 6
Chemical structure of piperine.
Figure 7
Figure 7
Chemical structure of thymoquinone.
Figure 8
Figure 8
Chemical structure of 17β-estradiol.
Figure 9
Figure 9
Chemical structure of hyaluronic acid.
Figure 10
Figure 10
Chemical structure of methylene blue.
Figure 11
Figure 11
Chemical structure of polysorbate 80.
See this image and copyright information in PMC

References

    1. Tamilselvan N., Raghavan C.V. Formulation and characterization of anti-alzheimer’s drug loaded chitosan nanoparticles and its In vitro biological evaluation. J. Young Pharm. 2015;7:28–35. doi: 10.5530/jyp.2015.1.6. - DOI
    1. Hassanzadeh G., Fallahi Z., Khanmohammadi M., Elmizadeh H. Effect of Magnetic Tacrine-Loaded Chitosan Nanoparticles on Spatial Learning, Memory, Amyloid Precursor Protein and Seladin-1 Expression in the Hippocampus of Streptozotocin-Exposed Rats. Int. Clin. Neurosci. J. 2016;3:25–31. doi: 10.22037/icnj.v3i1.12358. - DOI
    1. Ouyang Q.Q., Zhao S., Li S.D., Song C. Application of chitosan, chitooligosaccharide, and their derivatives in the treatment of Alzheimer’s disease. Mar. Drugs. 2017;15:322. doi: 10.3390/md15110322. - DOI - PMC - PubMed
    1. Ferri C.P., Prince M., Brayne C. Alzheimer’s Disease International. Global prevalence of dementia: A Delphi consensus study. Lancet. 2005;366:2112–2117. doi: 10.1016/S0140-6736(05)67889-0. - DOI - PMC - PubMed
    1. Macauley S.L., Holtzman D.M. Recent Advances from the Bench Toward the Bedside in Alzheimer’s Disease. EBioMedicine. 2015;2:94–95. doi: 10.1016/j.ebiom.2015.01.002. - DOI - PMC - PubMed

MeSH terms